临床药物基因组学项目中处方者对SLCO1B1基因型指导辛伐他汀临床决策支持系统的采纳情况
本研究前瞻性评估了临床药物基因组学项目中处方者对即时临床决策支持(CDS)的交互情况,该CDS用于指导初级保健患者的辛伐他汀治疗。在1,639例预先基因分型患者中,298例(18.2%)为中间功能(IF)OATP1B1表型,25例(1.53%)为功能不良(PF)表型。处方者接受了64.2%的即时CDS并导致处方变更,且他汀强度显著影响采纳率,而患者性别、种族、处方者类型或药物基因组学培训状态无显著影响。
要点
- 预先基因分型患者中18.2%为IF OATP1B1表型,1.53%为PF表型。
- 即时CDS的采纳率为64.2%,且采纳后均导致处方变更。
- 他汀强度显著影响处方者对CDS的采纳,其他因素无显著影响。
核心结论
- 初级保健提供者对于大多数拥有预先基因型数据的患者,能够顺利采纳药物基因组学信息来指导他汀治疗。
研究设计与样本
- 前瞻性评估处方者与即时临床决策支持(CDS)的交互,该CDS用于指导辛伐他汀治疗,研究对象为临床药物基因组学项目中纳入的多样化初级保健患者队列。
主要发现
- 在1,639例预先基因分型患者中,298例(18.2%)为中间功能(IF)OATP1B1表型,25例(1.53%)为功能不良(PF)表型。
- 64.2%的即时CDS被处方者接受并导致处方变更。
- 他汀强度显著影响处方者对药物基因组学指导的CDS的采纳,而患者性别或种族、处方者类型或药物基因组学培训状态无显著影响。
临床怎么用
- 在拥有预先基因型数据的初级保健患者中,处方者可利用即时CDS采纳药物基因组学信息来指导辛伐他汀治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacogenetic implementation programs are increasingly feasible due to the availability of clinical guidelines for implementation research. The utilization of these resources has been reported with selected drug-gene pairs; however, little is known about how prescribers respond to pharmacogenetic recommendations for statin therapy. We prospectively assessed prescriber interaction with point-of-care clinical decision support (CDS) to guide simvastatin therapy for a diverse cohort of primary care patients enrolled in a clinical pharmacogenetics program. Of the 1,639 preemptively genotyped patients, 298 (18.2%) had an intermediate function (IF) OATP1B1 phenotype and 25 (1.53%) had a poor function (PF) phenotype, predicted by a common single nucleotide variant in the SLCO1B1 gene (c.521T>C; rs4149056). Clinicians were presented with CDS when simvastatin was prescribed for patients with IF or PF through the electronic health record. Importantly, 64.2% of the CDS deployed at the point-of-care was accepted by the prescribers and resulted in prescription changes. Statin intensity was found to significantly influence prescriber adoption of the pharmacogenetic-guided CDS, whereas patient gender or race, prescriber type, or pharmacogenetic training status did not significantly influence adoption. This study demonstrates that primary care providers readily adopt pharmacogenetic information to guide statin therapy for the majority of patients with preemptive genotype data.
引用
- Obeng AO, Scott SA, Kaszemacher T, et al. Prescriber Adoption of SLCO1B1 Genotype-Guided Simvastatin Clinical Decision Support in a Clinical Pharmacogenetics Program. Clin Pharmacol Ther. 2022. PMID: 36372942. doi:10.1002/cpt.2773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。